ReShape Lifesciences (RSLS) announced that the company has received a Notice of Allowance from the U.S. Patent and Trademark Office, USPTO, for patent application 18/241,151, entitled, “Intragastric Device.” When issued, the patent will cover claims for an intragastric balloon system, comprising a swallowable capsule with a self-sealing fill valve and a degradable release valve designed to deflate and open the valve around three months after inflation with saline liquid, and configured for natural excretion after deflation, among other claim features. Once issued, the patent will provide protection into at least January 2031, without accounting for a potential Patent Term Extension, PTE.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RSLS:
- ReShape receives Notice of Allowance from USPTO for diabetes neuromodulation
- ReShape Lifesciences Reports 2024 Financial Results and Strategic Updates
- ReShape Lifesciences enters agreement with Haifa
- ReShape Lifesciences Delays Yearly Report Filing
- ReShape Lifesciences Faces Board Resignation Challenge
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue